DGAP-News

Epigenomics AG: Voluntary public takeover offer by Summit Hero Holding not successful

DGAP-News: Epigenomics AG / Key word(s): Offer Epigenomics AG: Voluntary public takeover offer by Summit Hero Holding not successful 12.07.2017 / 13:30 The issuer is solely responsible for the content of this announcement. Press release

Epigenomics AG: Voluntary public takeover offer by Summit Hero Holding not successful

Berlin, July 12, 2017 - Summit Hero Holding GmbH ("bidder") announced today that, as of expiry of the extended acceptance period at midnight (24:00 CEST) on July 7, 2017, 62.13 percent of Epigenomics outstanding shares have been tendered under the voluntary public takeover offer or were held by or attributed to the bidder. Consequently, the minimum acceptance threshold of 75.0 percent has not been reached.

Greg Hamilton, CEO of Epigenomics, commented: "It is unfortunate that the takeover offer has not been successful. We now will carefully explore alternative financing options for Epigenomics in order to successfully commercialize our products and develop innovative cancer tests."

Contact:

Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel [phone], Fax [phone], E-Mail: [e-mail]

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon(R), is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics' second product, Epi proLung(R), is in development as a blood-based test for lung cancer detection.

For more information, please visit www.epigenomics.com.

---

12.07.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Phone:	[phone]
Fax:	[phone]
E-mail:	[e-mail]
Internet:	www.epigenomics.com
ISIN:	DE000A11QW50
WKN:	A11QW5
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange

End of News	DGAP News Service

592109  12.07.2017